SCHEMBL15945904

SCHEMBL15945904

COCOc1ccc(C2CC(=O)c3c(OCOC)cc(C)cc3O2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROR1 Q01973 1/20 0.77
MAOB P27338 6/20 0.51
ALDH1A1 P00352 2/20 0.50
CYP3A4 P08684 2/20 0.50
KDM4E B2RXH2 1/20 0.50
HPGD P15428 1/20 0.50
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ABCG2 Q9UNQ0 1/20 0.50
CYP19A1 P11511 5/20 0.49
CYP1A1 P04798 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP1B1 Q16678 1/20 0.49
ADORA3 P0DMS8 1/20 0.47
MAPT P10636 1/20 0.47
ATM Q13315 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
TAS2R31 P59538 1/20 0.47
BCHE P06276 1/20 0.47
ACHE P22303 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14242303 0.91 ROR1 (0.91) ROR1MAOBALDH1A1CYP3A4KDM4E
SCHEMBL13708477 0.83 ROR1 (0.82) ROR1MAOBALDH1A1CYP3A4KDM4E
SCHEMBL18104369 0.82 ALDH1A1 (0.68) ROR1MAOBALDH1A1CYP3A4KDM4E
SCHEMBL18104378 0.82 ALDH1A1 (0.68) ROR1MAOBALDH1A1CYP3A4KDM4E
SCHEMBL18104325 0.80 ALDH1A1 (0.64) MAOBALDH1A1CYP3A4KDM4EHPGD
SCHEMBL10005479 0.76 BCHE (0.58) ROR1MAOBALDH1A1CYP3A4KDM4E
SCHEMBL22465616 0.76 ROR1 (0.69) ROR1ALDH1A1CYP3A4KDM4EHPGD
SCHEMBL25437506 0.75 MAOB (0.74) ROR1MAOBCYP3A4KDM4EMAPK1
SCHEMBL5421488 0.75 ROR1 (0.57) ROR1CYP3A4ABCG2CYP19A1MAPT
SCHEMBL13906136 0.74 CYP1A1 (0.80) MAOBALDH1A1CYP3A4HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160243132-A1 METHODS FOR INHIBITING MUSCLE ATROPHY UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2016-08-25 US disclosed
US-9295664-B2 Methods for lowering blood glucose UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2016-03-29 US disclosed
US-20140228333-A1 METHODS FOR INHIBITING MUSCLE ATROPHY UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2014-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160243132-A1 METHODS FOR INHIBITING MUSCLE ATROPHY CPT1B, MYOF, TNNC1 ROR1 4836/4885MAOB 1761/4885ALDH1A1 3806/4885
US-20140228333-A1 METHODS FOR INHIBITING MUSCLE ATROPHY CPT1B, MYOF, TNNC1 ROR1 4836/4885MAOB 1761/4885ALDH1A1 3806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.